Corporate Profile
| Company Name |
Nipro Pharma Corporation |
|---|---|
| Capital |
8,669 million yen (as of May, 2023) |
| Representative |
Takahiro Oichi, Representative Director and President |
| Head Office |
3-26, Senriokashinmachi, Settsu City, Osaka, 566-8510, Japan |
| Established |
August 1, 1948 |
| Incorporated |
July 25, 1950 |
| Number of employees |
4,177(as of March 2026) |
| Director & Auditor |
Takahiro Oichi,President Naoki Okamoto,Director Kumiko Kusuyama,Director Koki Kanazawa,Director Yasuo Nishida,Director Maeda Terutoshi,Outside Director Takehito Yogo,Auditor (as of June 22,2026) |
| Operating Officer |
Takashi Nakamichi,Senior Executive Officer Hisanori Miyawaki,Senior Executive Officer Tetsuhiro Mikami,Senior Executive Officer Naoya Nishimura,Senior Executive Officer Shohei Otani,Senior Executive Officer Masato Moriguchi,Senior Executive Officer Kengo Yamada,Operating Officer Yuki Tanaka,Operating Officer Takashi Nshii,Operating Officer Mitsutaka Okoshi,Operating Officer (as of June 22,2026) |
| Main business |
Manufacturing, sales, importing and exporting of pharmaceutical products |
| Production Bases／ Analysis Center |
Odate, Ise, Kagamiishi, |
| Group Companies |
Nipro Corporation, |
| Subsidiary Company |
Nipro Pharma Vietnam Co.,Ltd., |
| Main Bank of Account |
Mizuho Bank,Ltd., Resona Bank,Limited, |
| A member of |
The Federation of Pharmaceutical Manufacturers' Associations of Japan |
